Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue
Revenue	$ 600	$ 2,181
Cost of revenue
Cost of revenue	1,738	2,467
Gross loss	(1,138)	(286)
Operating Expenses
Research and development	3,934	5,655
Sales and marketing	4,253	7,674
General and administrative	3,349	4,560
Amortization of intangible assets	2,564	2,611
Change in fair value of contingent consideration	1,056	998
Restructuring and other charges	858	0
Acquisition related costs	0	45
Loss from sale of SurgiBot assets, net	0	97
Total Operating Expenses	16,014	21,640
Operating Loss	(17,152)	(21,926)
Other Income (Expense)
Change in fair value of warrant liabilities	(155)	(106)
Interest income	27	318
Interest expense	0	(1,116)
Other expense	(15)	(305)
Total Other Income (Expense), net	(143)	(1,209)
Loss before income taxes	(17,295)	(23,135)
Income tax benefit	697	610
Net loss	(16,598)	(22,525)
Deemed dividend related to beneficial conversion feature of preferred stock	(412)	0
Net loss attributable to common stockholders	(17,010)	(22,525)
Comprehensive loss
Foreign currency translation loss	(872)	(1,949)
Comprehensive loss	$ (17,470)	$ (24,474)
Net loss per common share attributable to common stockholders - basic and diluted (USD per share)	$ (0.59)	$ (1.35)
Weighted average number of shares used in computing net loss per common share - basic and diluted (in shares)	28,906	16,677
Product
Revenue
Revenue	$ 242	$ 1,829
Cost of revenue
Cost of revenue	913	1,273
Service
Revenue
Revenue	358	352
Cost of revenue
Cost of revenue	$ 825	$ 1,194